Loading...
OTCM
TLPPF
Market cap4.69bUSD
Apr 04, Last price  
13.66USD
1D
-14.92%
1Q
-5.31%
IPO
1,152.75%
Name

Telix Pharmaceuticals Ltd

Chart & Performance

D1W1MN
P/E
154.17
P/S
9.83
EPS
0.15
Div Yield, %
—
Shrs. gr., 5y
9.88%
Rev. gr., 5y
115.03%
Revenues
783m
+57.70%
0023,849,00023,021,00020,907,00024,359,00023,567,00021,191,00024,443,00014,399,00017,035,0005,213,0007,596,000160,096,000496,659,000783,207,000
Net income
50m
+857.95%
-289,000-497,000-2,584,000-1,129,000-2,500,0004,671,000-1,749,000-611,000-4,308,000-4,694,000-1,402,000-44,887,000-80,510,000-104,079,0005,211,00049,919,000
CFO
0k
-533,000323,000-1,203,000-1,617,000-2,561,000-772,000-810,000-1,068,000-4,337,0001,960,000-59,328,000-63,970,00000
Earnings
May 21, 2025

Profile

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
URL
https://telixpharma.com/
IPO date
Nov 15, 2017
Employees
234
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
783,207
57.70%
496,659
210.23%
160,096
2,007.64%
Cost of revenue
701,023
450,853
282,120
Unusual Expense (Income)
NOPBT
82,184
45,806
(122,024)
NOPBT Margin
10.49%
9.22%
Operating Taxes
6,137
(2,124)
5,457
Tax Rate
7.47%
NOPAT
76,047
47,930
(127,481)
Net income
49,919
857.95%
5,211
-105.01%
(104,079)
29.27%
Dividends
Dividend yield
Proceeds from repurchase of equity
999
6,652
165,407
BB yield
-7.32%
Debt
Debt current
21,486
1,559
641
Long-term debt
570,599
24,158
9,805
Deferred revenue
3,288
22,522
Other long-term liabilities
44,675
76,097
61,807
Net debt
(124,354)
(109,780)
(100,364)
Cash flow
Cash from operating activities
(63,970)
CAPEX
(14,322)
(10,794)
(13,861)
Cash from investing activities
(135,173)
(25,489)
(16,997)
Cash from financing activities
638,923
10,186
174,960
FCF
52,219
36,275
(139,990)
Balance
Cash
710,346
123,237
116,329
Long term investments
6,093
12,260
(5,519)
Excess cash
677,279
110,664
102,805
Stockholders' equity
(28,563)
148,911
80,007
Invested Capital
1,226,187
131,789
83,111
ROIC
11.20%
44.61%
ROCE
6.81%
18.89%
EV
Common stock shares outstanding
310,644
Price
24.61
144.15%
10.08
38.65%
7.27
-6.19%
Market cap
2,258,382
3.26%
EV
2,158,018
EBITDA
82,184
45,806
(116,645)
EV/EBITDA
Interest
36,491
13,136
406
Interest/NOPBT
44.40%
28.68%